Molecular mechanism
Amylin and calcitonin receptors
The calcitonin receptor, and the amylin receptor complexes it forms when associated with receptor activity-modifying proteins RAMP1, RAMP2 or RAMP3. Because the amylin receptors are heteromers rather than distinct gene products, receptor construct and accessory-protein expression must accompany any selectivity claim; a potency ranking is not transferable between assay systems.
See this target on the receptor map
01
Neutral molecular overview
The calcitonin receptor, and the amylin receptor complexes it forms when associated with receptor activity-modifying proteins RAMP1, RAMP2 or RAMP3. Because the amylin receptors are heteromers rather than distinct gene products, receptor construct and accessory-protein expression must accompany any selectivity claim; a potency ranking is not transferable between assay systems.
02
Target identifiers
- Gene symbols
- CALCR, RAMP1, RAMP2, RAMP3
03
Related compounds
Compound
Amylin (human IAPP)
Amylin is the endogenous 37-residue human pancreatic peptide hormone, co-secreted with insulin, from which pramlintide and cagrilintide are both derived.
Compound
Cagrilintide
Cagrilintide is a long-acting synthetic amylin analog, lipidated and disulfide-cyclized, characterised at the calcitonin receptor and at amylin receptor complexes.
Compound
Pramlintide
Pramlintide is an engineered analog of human amylin carrying three proline substitutions, designed to address the aggregation behaviour of the native human sequence.
04
Related mechanisms
No related mechanism is declared in this seed record.
05
Verified bibliography
Reference 1
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.Cao J, Belousoff MJ, Johnson RM, Keov P, Mariam Z, Deganutti G, Christopoulos G, Hick CA, Reedtz-Runge S, Glendorf T, Ballarín-González B, Raun K, Bayly-Jones C, Wootten D, Sexton PM
Nature communications · 2025-04-10 · Journal Article
currentReference 2
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.Carvas AO, Leuthardt A, Kulka P, Lommi G, Hassan S, Coester B, Lundh S, Pers T, Secher A, Raun K, Lutz TA, Le Foll C
EBioMedicine · 2025-07-03 · Journal Article
currentReference 3
Development of Cagrilintide, a Long-Acting Amylin Analogue.Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K
Journal of medicinal chemistry · 2021-07-21 · Journal Article
current
Study models of these references
What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.
| Reference | Study models |
|---|---|
| Cao J et al. 2025 | Study models reported: in vitro · from the abstract |
| Carvas AO et al. 2025 | Study models reported: animal (mouse) · from the abstract |
| Kruse T et al. 2021 | Study models reported: in vitro; animal (rat) · from the full text |
06
Related glossary terms
07
Related Purely Peptides research articles
No existing Research Article is mapped to this mechanism seed record.